10-K: Kewaunee Scientific Fiscal 2026 Annual Results

Kewaunee Scientific Corporation reports fiscal 2026 net earnings of $9.6 million, driven by the integration of the Nu Aire acquisition and international project deliveries.

Summary

• Net sales for fiscal year 2026 were $282.0 million, up from $240.5 million in fiscal year 2025.
• Net earnings attributable to the Company were $9.6 million, or $3.22 per diluted share, compared to $11.4 million, or $3.83 per diluted share, in the prior year.
• The Lab Products Group (LPG) segment saw sales increase 19.8% to $214.9 million, largely due to the Nu Aire acquisition.
• International segment sales grew 9.9% to $67.1 million, benefiting from the delivery of previously delayed projects in India.
• Order backlog at April 30, 2026, stood at $165.9 million, down from $214.6 million at the end of fiscal 2025.
• The Company successfully completed the repayment of $23.0 million in subordinated seller notes related to the Nu Aire acquisition.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a stable performance reflecting a strategic transition period; while earnings and backlog declined, the successful integration of a major acquisition and debt reduction provide a solid foundation for future growth.

Positives

• Successful integration of the Nu Aire acquisition, which expanded the product portfolio and market reach.
• Strong revenue growth in both the LPG and International segments.
• Significant reduction in acquisition-related debt through the repayment of $23.0 million in seller notes.
• Maintained a healthy current ratio of 2.2-to-1.0.
• Operating activities provided $18.6 million in cash, an improvement over the $14.8 million provided in the prior year.

Negatives

• Net earnings declined year-over-year from $11.4 million to $9.6 million.
• Order backlog decreased significantly to $165.9 million from $214.6 million.
• Operating expenses increased to $63.7 million from $51.1 million, driven by acquisition-related costs and higher SG&A.
• Interest expense rose to $3.9 million from $3.2 million due to debt incurred for the Nu Aire acquisition.

Risks

• Concentration risk: 34% of sales are derived from three domestic channel partners.
• Exposure to construction industry volatility and potential project delays.
• Reliance on sole or limited sources of supply for certain raw materials and components.
• Risks associated with international operations, including foreign currency fluctuations and geopolitical instability.
• Potential for goodwill and intangible asset impairment charges.
• Cybersecurity threats and potential IT system disruptions.

Future Outlook

The Company remains focused on disciplined capital allocation, operational execution, and serving customers. It anticipates fiscal year 2027 capital expenditures of approximately $6.0 million, to be funded by operating activities and the revolving credit facility.

Management Comments

• The acquisition of Nu Aire presented a unique opportunity to combine robust capabilities with a recognized market leader.
• The Company remains focused on disciplined capital allocation, operational execution, and serving our customers with excellence.

Industry Context

StockSavvy.ai notes that Kewaunee is navigating a challenging construction environment by diversifying its portfolio through the Nu Aire acquisition, positioning itself as a more comprehensive provider in the life sciences and laboratory infrastructure space.

Comparison to Industry Standards

• The company's focus on competitive public bidding is standard for the laboratory furniture industry.
• The use of retention amounts in contracts is consistent with industry practices for construction-related projects.
• The company's reliance on a few large channel partners is a common risk factor for specialized manufacturing firms in this sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ordinary course disputes and litigation, none of which are expected to have a material adverse effect.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders: Impacted by the decline in net earnings and the reduction in order backlog.
• Employees: Continued investment in workforce and wellness programs.
• Customers: Benefit from expanded product portfolio following the Nu Aire acquisition.

Next Steps

• Hold annual meeting of stockholders on August 26, 2026.
• Continue integration of Nu Aire operations.
• Execute capital expenditure plan of $6.0 million for fiscal 2027.

Key Dates

Recommendation

The company is in a transition phase following a significant acquisition. While the integration is progressing and debt is being managed, the decline in backlog and earnings suggests a cautious approach until growth trends stabilize.

Keywords

laboratory furniture, Nu Aire, scientific equipment, KEQU, biotechnology, healthcare infrastructure, 10-K